bioRxiv Science⌕ Search

Biology subjects

Post, L.

Publications and source records attributed to Post, L..

4 recordsLinked to original sources

PP2B-dependent cerebellar plasticity sets the amplitude of an innate reflex during juvenile development

Throughout life, the cerebellum plays a central role in the coordination and optimization of movements, using cellular plasticity to adapt a range of behaviors. If these plasticity processes establish a fixed setpoint during development, or continuously adjust behaviors throughout life, is currently unclear. Here, by spatiotemporally manipulating the activity of protein phosphatase 2B (PP2B), an enzyme critical for cerebellar plasticity, we examined the consequences of disrupted plasticity on the performance and adaptation of the vestibulo-ocular reflex (VOR). We find that, in contrast to Purkinje cell specific deletion starting early postnatally, acute pharmacological as well as adult-onset genetic deletion of PP2B affects all forms of VOR adaptation, but not the level of VOR itself. Next, we show that Purkinje cell-specific genetic deletion of PP2B in juvenile mice leads to a progressive loss of the protein PP2B and a concurrent change in the VOR, in addition to the loss of adaptive abilities. Finally, re-expressing PP2B in adult mice that lack PP2B expression from early in development, rescues VOR adaptation, but does not affect the performance of the reflex. Together, our results indicate that chronic or acute, genetic or pharmacological block of PP2B disrupts the adaptation of the VOR. In contrast, only the absence of plasticity during cerebellar development affects the setpoint of VOR, an effect that cannot be corrected after maturation of the cerebellum. These findings suggest that cerebellar plasticity influences behavior in two ways, through direct control of behavioral adaptation and via long-term effects initiated in the juvenile period. Significance StatementEarly damage to motor adaptation structures, such as the cerebellum, has been linked to neurodevelopmental disorders persisting into adulthood. Understanding these long-term effects requires disentangling the persistent, long-term effects of disrupted development from the acute, ongoing effects directly caused by the continuous presence of the disruption. Here, we demonstrate that disruptions during early development affect both basal level and adaptation, whereas late, adult-onset disruption of cerebellar plasticity only affects the ability to adapt, not the setpoint of an innate reflex. Our findings that specifically the absence of plasticity during cerebellar development affects the setpoint of VOR, which cannot be corrected by re-instating plasticity after maturation of the cerebellum, supports the concept of a sensitive developmental period for setting innate reflexes.

neuroscience↗

Identification of resistance mechanisms to small-molecule inhibition of TEAD-regulated transcription

The Hippo tumour suppressor pathway controls transcription by regulating nuclear abundance of YAP and TAZ, which activate transcription with the TEAD1-TEAD4 DNA-binding proteins. Recently, several small-molecule inhibitors of YAP and TEADs have been reported, with some now entering clinical trials for different cancers. Here, we investigated the cellular response to TEAD palmitoylation inhibitors, using a combination of genomic and genetic strategies. Genome-wide CRISPR/Cas9 screens identified genes that modulate the cellular response to TEAD inhibition, including members of the Hippo, MAPK and JAK-STAT signaling pathways. By exploring gene expression programs of mutant cells, we found that MAPK pathway hyperactivation confers resistance to TEAD inhibition by reinstating expression of a subset of YAP/TEAD target genes. Consistent with this, combined inhibition of TEAD and the MAPK protein MEK, synergistically blocked proliferation of several mesothelioma and lung cancer cell lines and more potently reduced the growth of patient-derived lung cancers in vivo. Collectively, we reveal mechanisms by which cells can overcome small-molecule inhibition of TEADs and potential strategies to enhance the anti-tumor activity of emerging Hippo pathway targeted therapies.

cancer biology↗

Adult Camk2a gene reinstatement restores the learning and plasticity deficits of Camk2a knockout mice

With the recent findings that mutations in the gene encoding the -subunit of calcium/calmodulin-dependent protein kinase II (CAMK2A) causes neurodevelopmental disorder (NDD), it is of great therapeutic relevance to know if there a critical developmental time window in which CAMK2A needs to be expressed for normal brain development, or whether expression of the protein at later stages is still beneficial to restore normal functioning. To answer this question, we generated an inducible Camk2a mouse model, which allows us to express CAMK2A at any desired time. Here, we show that adult expression of CAMK2A rescues the behavioural and electrophysiological phenotypes seen in the Camk2a knock-out mice, including spatial and conditional learning and synaptic plasticity. These results suggest that CAMK2A does not play a critical irreversible role in neurodevelopment, which is of importance for future therapies to treat CAMK2A-dependent disorders.

neuroscience↗

A focal adhesion kinase-YAP signaling axis drives drug tolerant persister cells and residual disease in lung cancer

Targeted therapy is effective in many tumor types including lung cancer, the leading cause of cancer mortality. Paradigm defining examples are targeted therapies directed against non-small cell lung cancer (NSCLC) subtypes with oncogenic alterations in EGFR, ALK and KRAS. The success of targeted therapy is limited by drug-tolerant tumor cells which withstand and adapt to treatment and comprise the residual disease state that is typical during treatment with clinical targeted therapies. Here, we integrate studies in patient-derived and immunocompetent lung cancer models and clinical specimens obtained from patients on targeted therapy to uncover a focal adhesion kinase (FAK)-YAP signaling axis that promotes residual disease during oncogenic EGFR-, ALK-, and KRAS-targeted therapies. FAK-YAP signaling inhibition combined with the primary targeted therapy suppressed residual drug-tolerant cells and enhanced tumor responses. This study unveils a FAK-YAP signaling module that promotes residual disease in lung cancer and mechanism-based therapeutic strategies to improve tumor response.

cancer biology↗